Drugs Containing Excipient (Inactive Ingredient) PARAFFIN
✉ Email this page to a colleague
Branded drugs containing PARAFFIN excipient, and estimated key patent expiration / generic entry dates
Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
---|---|---|---|---|---|
AbbVie Inc | K-TAB | potassium chloride | 0074-3278 | PARAFFIN | |
AstraZeneca Pharmaceuticals LP | TOPROL | metoprolol succinate | 0186-1088 | PARAFFIN | |
GlaxoSmithKline Consumer Healthcare Holdings (US) LLC | NEXIUM 24HR | esomeprazole magnesium | 0573-2451 | PARAFFIN | |
PharmaDerm a division of Fougera Pharmaceuticals Inc | CUTIVATE | fluticasone propionate | 10337-333 | PARAFFIN | |
The Procter & Gamble Manufacturing Company | PRILOSEC OTC | omeprazole magnesium | 37000-455 | PARAFFIN | |
ProStrakan Inc | RECTIV | nitroglycerin | 42747-235 | PARAFFIN | |
>Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Generic drugs containing PARAFFIN excipient
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.